Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity

Journal of Clinical Investigation

Volumn 124, Issue 2, 2014, Pages 528-542

  Kagoya, Yuki ^a   Yoshimi, Akihide ^a   Kataoka, Keisuke ^a   Nakagawa, Masahiro ^a   Kumano, Keiki ^a   Arai, Shunya ^a   Kobayashi, Hiroshi ^a   Saito, Taku ^a   Iwakura, Yoichiro ^b   Kurokawa, Mineo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE TRANSPORT, CELL NUCLEUS; ADULT; AGED; ANIMALS; BONE MARROW CELLS; BORONIC ACIDS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; NF-KAPPA B; PHENOTYPE; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893858504     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI68101     Document Type: Article

References (52)

1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3(7):730-737.
2. Lapidot T, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645-648.
3. Ishikawa F, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007; 25(11):1315-1321.
4. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011; 29(5):475-486.
5. Mardis ER, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058-1066.
6. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-κB by a posttranslational mechanism. Cell. 1986;47(6):921-928.
7. La Rosa FA, Pierce JW, Sonenshein GE. Differential regulation of the c-myc oncogene promoter by the NF-κB rel family of transcription factors. Mol Cell Biol. 1994;14(2):1039-1044.
8. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19(8):5785-5799.
9. Duckett CS. Apoptosis and NF-κB: the FADD connection. J Clin Invest. 2002;109(5):579-580.
10. Karin M, Greten FR. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749-759.
11. Karin M. Nuclear factor-κB in cancer development and progression. Nature. 2006;441(7092):431-436.
12. Pikarsky E, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431(7007):461-466.
13. Guzman ML, et al. Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98(8):2301-2307.
14. Guzman ML, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A. 2002;99(25):16220-16225.
15. Frelin C, et al. Targeting NF-κB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood. 2005;105(2):804-811.
16. Carvalho G, et al. Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene. 2007;26(16):2299-2307.
17. Guzman ML, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 2007;110(13):4427-4435.
18. Jenkins C, et al. Nuclear factor-κB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia. Br J Haematol. 2008;143(5):661-671.
19. Jin Y, et al. Antineoplastic mechanism of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-κB pathway and generation of reactive oxygen species. Cancer Res. 2010;70(6):2516-2527.
20. Takahashi S, et al. Over-expression of Flt3 induces NF-κB pathway and increases the expression of IL-6. Leuk Res. 2005;29(8):893-899.
21. Liu S, et al. Sp1/NFκB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 2010;17(4):333-347.
22. Nakagawa M, et al. AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors. Blood. 2011; 118(25):6626-6637.
23. Eppert K, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011;17(9):1086-1093.
24. Sarry JE, et al. Human acute myelogenous leukemia stem cells are rare and heterogenous when assayed in NOD/SCID/IL2Rκc-deficient mice. J Clin Invest. 2011;121(1):384-395.
25. Liu T, et al. Functional characterization of meningioma 1 as collaborating oncogene in acute leukemia. Leukemia. 2010;24(3):601-612.
26. Kvinlaug BT, et al. Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Res. 2011; 71(12):4117-4129.
27. Neering SJ, et al. Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood. 2007;110(7):2578-2585.
28. Wang Y, et al. The Wnt/κ-catenin pathway is required for the development ofleukemia stem cells in AML. Science. 2010;327(5973):1650-1653.
29. Hinz M, et al. Nuclear factor κB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med. 2002;196(5):605-617.
30. Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA. 2010;304(24):2706-2715.
31. Kishore N, et al. A selective IKK-2 inhibitor blocks NF-κB- dependent gene expression in interleukin-1 κ-stimulated synovial fibroblasts. J Biol Chem. 2003;278(35):32861-32871.
32. Algül H, et al. Pancreas-specific RelA/p65 truncation increases susceptibility of acini to inflammation-associated cell death following cerulein pancreatitis. J Clin Invest. 2007;117(6):1490-1501.
33. Beg AA, Finco TS, Nantermet PV, Baldwin AS Jr. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IκBα: a mechanism for NF-κB activation. Mol Cell Biol. 1993;13(6):3301-3310.
34. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007;9(4):212.
35. McLean MH, et al. The inflammatory microenvironment in colorectal neoplasia. PLoS One. 2011; 6(1):e15366.
36. Charles KA, et al. The tumor-promoting actions of TNF-κinvolve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest. 2009; 119(10):3011-3023.
37. Moore RJ, et al. Mice deficient in tumor necrosis factor-αare resistant to skin carcinogenesis. Nat Med. 1999;5(7):828-831.
38. Popivanova BK, et al. Blocking TNF-κin mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008;118(2):560-570.
39. Egberts JH, et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2008;68(5):1443-1450.
40. Li J, et al. TNF-αinduces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells. J Clin Invest. 2007;117(11):3283-3295.
41. Hoang T, Levy B, Ouetto N, Hainan A, Rodriguez-Cimadevilla JC. Tumor necrosis factor α stimulates the growth of the clonogenic cells of acute myeloblastic leukemia in synergy with granulocyte-macrophage colonystimulating factor. J Exp Med. 1989;170(1):15-26.
42. Khoury E, et al. Tumor necrosis factor alpha (TNF α) downregulates c-kit proto-oncogene product expression in normal and acute myeloid leukemia CD34+ cells via p55 TNF alpha receptors. Blood. 1994;84(8):2506-2514.
43. Zhang B, et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell. 2012; 21(4):577-592.
44. Kerbauy DM, Lesnikov V, Abbasi N, Seal S, Scott B, Deeg HJ. NF-κB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplasticsyndromes (MDSs). Blood. 2005;106(12):3917-3925.
45. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 2004;5(5):417-421.
46. Chen L, Madura K. Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res. 2005;65(13):5599-5606.
47. Stein SJ, Baldwin AS. Deletion of the NF-κB subunit p65/RelA in the hematopoietic compartment leads to defects in hematopoietic stem cell function. Blood. 2013;121(25):5015-5024.
48. Iversen PO, Wiig H. Tumor necrosis factor α and adiponectin in bone marrow interstitial fluid from patients with acute myeloidleukemia inhibit normal hematopoiesis. Clin Cancer Res. 2005; 11(19 pt 1):6793-6799.
49. Pronk CJ, Veiby OP, Bryder D, Jacobsen SE. Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of 2 distinct receptors. J Exp Med. 2011;208(8):1563-1570.
50. Taniguchi T, Takata M, Ikeda A, Momotani E, Sekikawa K. Failure of germinal center formation and impairment of response to endotoxin in tumor necrosis factor alpha-deficient mice. Lab Invest. 1997; 77(6):647-658.
51. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the Comparative C(T) method. Nat Protoc. 2008;3(6):1101-1108.
52. Jain AK, Bloom DA, Jaiswal AK. Nuclear import and export signals in control of Nrf2. J Biol Chem. 2005;280(32):29158-29168.